Company Overview
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Why Investors Should Care
Generates a return on equity of 28.4%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $29.64M (-355.3% YoY); net profit $-23.96M.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +386.50% |
| 6 Months: | -4.83% |
| 3 Months: | +6.44% |
| 1 Month: | -0.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 28.4%.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 30.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NBTX Nanobiotix S.A. PHARMA | 38.19 | -65.84 | $1.94B | 0.00% | -105.51% | 28.36% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 30.06M | -11.61M | 29.64M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 46.70M | 56.84M | 56.78M | 40.46M |
| Operating Income | - | -46.70M | -26.78M | -68.39M | -10.82M |
| EBITDA | - | -49.70M | -30.09M | -58.33M | -12.07M |
| Interest Expense | - | 5.84M | 7.98M | 8.09M | 10.39M |
| Pretax Income | - | -57.03M | -39.58M | -68.03M | -23.96M |
| Tax Provision | - | 10.00K | 120.00K | 101.00K | 3.00K |
| Net Income | - | -57.04M | -39.70M | -68.13M | -23.96M |
| Diluted EPS | - | -1.64 | -1.08 | -1.44 | -0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 59.77M | 93.90M | 67.42M | 67.76M |
| Current Assets | - | 52.36M | 87.34M | 61.47M | 62.75M |
| Cash & Equivalents | - | 41.39M | 75.28M | 49.74M | 52.75M |
| Inventory | - | - | - | - | - |
| Receivables | - | 101.00K | 905.00K | 2.98M | 2.14M |
| Total Liabilities | - | 86.81M | 95.74M | 133.12M | 152.24M |
| Current Liabilities | - | 37.94M | 49.87M | 58.94M | 57.51M |
| Long Term Debt | - | 44.04M | 41.66M | 43.01M | 89.12M |
| Total Debt | - | 53.17M | 50.56M | 50.90M | 95.32M |
| Total Equity | - | -27.05M | -1.84M | -65.70M | -84.48M |
| Shares Outstanding | - | 34.88M | 47.13M | 47.43M | 48.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -37.10M | -12.48M | -19.55M | -33.42M |
| Investing Cash Flow | - | 138.00K | -349.00K | -955.00K | -578.00K |
| Financing Cash Flow | - | -5.65M | 46.77M | -5.13M | 37.42M |
| Capital Expenditure | - | -93.00K | -337.00K | -848.00K | -546.00K |
| Free Cash Flow | - | -37.20M | -12.81M | -20.40M | -33.97M |
| Net Change in Cash | - | -42.62M | 33.95M | -25.64M | 3.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | -89.1% | 589.1% | -36.5% |
| Net Margin % | - | - | -132.1% | 586.8% | -80.8% |
| ROE % | - | 210.9% | 2,152.9% | 103.7% | 28.4% |
| ROCE % | - | -213.9% | -60.8% | -806.2% | -105.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 11.11% | 5.62M | $185.87M |
| 2 | Morgan Stanley | 0.10% | 49.79K | $1.65M |
| 3 | Jane Street Group, LLC | 0.06% | 32.18K | $1.06M |
| 4 | HRT Financial LP | 0.05% | 27.33K | $903.32K |
| 5 | Optiver Holding B.v. | 0.03% | 13.63K | $450.50K |
| 6 | Xtx Topco Ltd | 0.03% | 15.86K | $524.01K |
| 7 | Marshall Wace LLP | 0.02% | 10.04K | $331.95K |
| 8 | BNP Paribas Financial Markets | 0.01% | 4.04K | $133.65K |
| 9 | UBS Group AG | 0.01% | 2.58K | $85.17K |
| 10 | Citadel Advisors Llc | 0.01% | 6.04K | $199.69K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NBTX
Understanding Momentum Shifts in (NBTX) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxONk5JTlozUndRNXpYU05ZempDeUxsbHJINjJuajlqZF80MlNzbHd5T2RoTEt2OWF5UTNsNmJQakwyWEdESDdLZ0Y2UndYbnYxYUNsZFUzQVg1cjljekVZd2NHMDJ3emRLU01pSXhHdS1lTnd3dFhPQUxYWTJ4ZktXR1JzakdBdXZuaXBRU1…
Nanobiotix (NASDAQ: NBTX) updates share count and votes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOamlSZTl1S0FjU2l2SkRYdnBBWEVUOU1oT3dhVmJHaDRZdnRSTHlkdjU3cVZBaGx5eHpPVnJQbkFsdWR5NjFDZGNISXI0N1BJWkc3R28tZzMtVFhsZjc1czdSOHlVaXNxLWlQTWNJN29mVE1WVjVUSDZHZWZ0cy13LVk2ZWdIcW5OY0NKYX…
NBTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBaQW9rX0trRG5jeWdTdGpVR3NsMUZiaEdDTzhRZUxqOGw0cjJaMk1EWjJqenY3NVFGdkk2by1EOG1KcWI2NFE?oc=5" target="_blank">NBTX</a> <font color="#6f6f6f">Finviz</font>…
Nanobiotix (NBTX) Provides Update on Operational Progress - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQYUlWMWVTdDdabXM4WGJJdHhsQkNGc0IydFF2TVFlZWFRNWdsM2JjUDF1NHQ1dDV4WUNIYThmTGM2dXg2RzVtZnljNXFUZVFjZlNjV2lCNVV1SmRoZlNONXpKNzkxTXFESW5YbmcycU9lNm9UUzY5ZmNrMHA4X1dyTFdIVVUxWmtfSVJSNS…
Nanobiotix stock gains after J&J buyout rumors (NBTX:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNVJKb093V1BnOUlmc2p6TExXWTMxQmtiSzVTTU94U2V0QV9qZHBIMWFKVXExN1ZFaUFTOXBnc0VoRTFUc0dEM3RfRklVZ0ZLYUxvSUlodFRmOXU4YTU3ZnROeTh3NlkwU3laNnBEMUtiM0hMMmgwMjRGVDZNMGxVT2ZnWUkwSjFSaEJB?o…
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOeUlLQlNDU2o0MUpKYkJvLVhldnNXV3ppbG9hbGNFZk9ITHduMWJkZFdZam95Vld6X09nbVJiQUFzLUVnSG9jdTVfajQ1V1RmX3ZQbHd6elZmeW1jM1lCNFV3SnBhY1l3cDBYeG9vRDdWNGRqWWJzSEhRUlJ6dXNva2dkWndlU0YzbFB1bj…
NBTX — Frequently Asked Questions
What is the current share price of Nanobiotix S.A. (NBTX)?
As of 2026-09-19 21:16 PDT, Nanobiotix S.A. (NBTX) trades at $38.19 on NasdaqGS. Its 52-week range is $7.85 to $55.07.
What is the market capitalisation of NBTX?
Nanobiotix S.A. (NBTX) has a market capitalisation of $1.94B on NasdaqGS.
What is the P/E ratio of NBTX?
NBTX trades at a trailing price-to-earnings (P/E) ratio of -65.84. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -16.33.
What is the return on equity (ROE) of NBTX?
NBTX has a return on equity (ROE) of 28.36%. Its return on capital employed (ROCE) is -105.51%.
Is NBTX a good stock to buy?
This page provides a data-driven analysis of Nanobiotix S.A. (NBTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.